The role of pasireotide in the treatment of acromegaly

Affiliations

Comment

Nicholas A Tritos. Lancet Diabetes Endocrinol. 2014 Nov.

. 2014 Nov;2(11):855-6.

doi: 10.1016/S2213-8587(14)70175-5. Epub 2014 Sep 24.

¹ Neuroendocrine Unit, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA. Electronic address: ntritos@partners.org.

No abstract available

Comment on

Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
Gadelha MR, Bronstein MD, Brue T, Coculescu M, Fleseriu M, Guitelman M, Pronin V, Raverot G, Shimon I, Lievre KK, Fleck J, Aout M, Pedroncelli AM, Colao A; Pasireotide C2402 Study Group. Gadelha MR, et al. Lancet Diabetes Endocrinol. 2014 Nov;2(11):875-84. doi: 10.1016/S2213-8587(14)70169-X. Epub 2014 Sep 24. Lancet Diabetes Endocrinol. 2014. PMID: 25260838 Clinical Trial.